KCT0003820招募中未知
A phase II study of palbociclib for recurrent or refractory advanced thymic epithelial tumor
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 33
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 18(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •1.Histologically proven thymic epithelial tumor (TET) patients
- •2.Be =18 years of age on day of signing informed consent.
- •3.Documented progressive disease according to RECIST v1.1 following receipt of at least one cytotoxic chemotherapy regimen administered for inoperable or metastatic disease.
- •4.Measurable disease as defined per RECIST v 1.1. Tumor lesions previously irradiated or subjected to other locoregional therapy will only be deemed measurable if disease progression at the treated sited after completion of therapy is clearly documented.
- •5.Availability of a tumor tissue specimen (ie, archived formalin fixed paraffin embedded tissue [block preferred, or 10 unstained slides]), which will be used for retrospective biomarker analysis. If archived tumor tissue is not available, then a de novo biopsy will be required for patient participation.
- •6.ECOG performance status of 0 to 2
- •7.Adequate organ function as evidence by the following;
- •Absolute neutrophil count = 1.5 x 109/L
- •Platelets > 75 x 109/L
- •Hemoglobin (Hb) = 9g/dL
- •Estimated creatinine clearance = 40mL/min as calculated using the method standard for the institution
- •Total serum bilirubin =1.5 X UNL
- •AST and/or ALT < 5 X UNL
- •8.Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
- •9.Patients who are willing and able to comply with scheduled visit, treatment plan, laboratory test, and other study procedure.
排除标准
- •1.Known active uncontrolled or symptomatic central nervous system (CNS) metastases, carcinomatous meningitis, or leptomeningeal disease as indicated by clinical symptoms, cerebral edema, and/or progressive growth. Patients with a history of CNS metastases or cord compression are eligible if they have been definitively treated with local therapy (eg, radiotherapy, stereotactic surgery) and are clinically stable off anticonvulsants and steroids for at least 4 weeks before randomization.
- •2.Inability to swallow capsules.
- •3.Prior treatment with any CDK4/6 inhibitor.
- •4.Patients treated within the last 7 days prior to administration of palbociclib with:
- •Food or drugs that are known to be strong CYP (cytochrome P-450) 3A4 inhibitors (ie, amprenavir, atazanavir, boceprevir, clarithromycin, conivaptan, delavirdine, diltiazem, erythromycin, fosamprenavir, indinavir, itraconazole, ketoconazole, lopinavir, mibefradil, miconazole, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, verapamil, voriconazole, and grapefruit or grapefruit juice)
- •Drugs that are known to be strong CYP3A4 inducers (ie, carbamazepine, felbamate, nevirapine, phenobarbital, phenytoin, primidone, rifabutin, rifampin, rifapentin, and St. John’s wort)
- •Drugs that are known to prolong the QT interval
- •5.Major surgery, chemotherapy, radiotherapy, any investigational agents, or other anti-cancer therapy within 2 week before administration of palbociclib.
- •6.Diagnosis of any other malignancy within 3 years prior to administration of palbociclib, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix.
- •7.QTc > 480msec (based on the mean value of the triplicate electrocardiograms (ECGs), family or personal history of long or short QT syndrome, Brugada syndrome or known history of QTc prolongation, or Torsade de Pointes.
- •8.Uncontrolled electrolyte disorders that can compound the effects of a QTc-prolonging drug (eg, hypocalcemia, hypokalemia, hypomagnesemia).
- •9.Any of the following within 6 months of administration of palbociclib: myocardial infarction, severe/unstable angina, ongoing cardiac dysrhythmias of NCI CTCAE version 4.03 Grade >2, atrial fibrillation of any grade, symptomatic congestive heart failure, cerebrovascular accident, or symptomatic pulmonary embolism.
- •10.Active inflammatory bowel disease or chronic diarrhea, short bowel syndrome, or any upper gastrointestinal surgery including gastric resection that could impair drug absorption.
- •11.Known human immunodeficiency virus infection.
- •12.Other severe acute or chronic medical or psychiatric condition, including recent (within the past year) or active suicidal ideation or behavior, or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
- •13.Pregnant or nursing women. Male and female subjects of childbearing potential who are unwilling or unable to use two highly effective methods of contraception as outlined in this protocol for the duration of the study and for 6 months after the last dose of palbociclib.
研究者
相似试验
招募中
1 期
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Solid TumorsCTRI/2022/04/042263Pfizer Inc
招募中
不适用
The assess the safety and the clinical anti-tumor activity of exemestane plus GnRH agonist acetate in combination with palbociclib vs capecitabine in premenopausal hormone receptor-positive advanced breast cancer patients.KCT0003346Samsung Medical Center182
进行中（未招募）
1 期
A research study of Palbociclib plus Fulvestrant for patients who previously received endocrine treatment and whose breast cancer has spread to other parts of the bodyPatients with endocrine-resistant metastatic or locally relapsed breast cancer not amenable to treatment with a curative intent ER+/HER2-, enrolled in the AURORA studyMedDRA version: 21.1Level: LLTClassification code 10072737Term: Advanced breast cancerSystem Organ Class: 100000004864EUCTR2014-005387-15-ITINTERNATIONAL BREAST CANCER STUDY GROUP120
进行中（未招募）
1 期
A research study of Palbociclib plus Fulvestrant for patients who previously received endocrine treatment or one prior chemotherapy and whose breast cancer has spread to other parts of the bodyPatients with endocrine-resistant metastatic or locally relapsed, ER+/HER2-negative breast cancer not amenable to treatment with a curative intent enrolled in the AURORA study.MedDRA version: 21.1Level: LLTClassification code 10072737Term: Advanced breast cancerSystem Organ Class: 100000004864EUCTR2014-005387-15-BEETOP IBCSG Partners Foundation120
进行中（未招募）
1 期
A study for patients with metastatic breast cancer (hormone receptor-positive, negative HER2 and resistance to non-steroidal aromatase inhibidors) comparing palbociclib + exemestane versus capecitabine.Patients with hormonal receptor positive and HER2 negative MBC who are resistant to prior NSAI therapy.MedDRA version: 19.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2013-003170-27-IEGEICAM (Fundación Grupo Español de Investigación en Cáncer de Mama)550